Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics

The relative bioavailability of lanabecestat administered as 2 tablet formulations versus an oral solution was investigated. This phase 1 single‐center, open‐label, randomized, 3‐period crossover study involved healthy male and nonfertile female subjects aged 18–55 years (NCT02039180). Subjects rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Naidong, Monk, Scott A., Daga, Pankaj, Bender, David M., Rosen, Laura B., Mullen, Jamie, Minkwitz, Margaret C., Kugler, Alan R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947295/
https://www.ncbi.nlm.nih.gov/pubmed/29319935
http://dx.doi.org/10.1002/cpdd.422

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947295/
https://www.ncbi.nlm.nih.gov/pubmed/29319935
http://dx.doi.org/10.1002/cpdd.422

Ejemplares similares